C31H38F2N8O
Neat
576.70
Zandelisib; 1401436-95-0; PWT143; ACC-524; PW-143; 8Z28M5SX0X; 1, 3, 5-Triazin-2-amine, 4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-N-[1, 1-dimethyl-2-[2-(1-methyl-4-piperidinyl)phenyl]ethyl]-6-(4-morpholinyl)-; 1, 3, 5-Triazin-2-amine, 4-(2-(difluoromethyl)-1H-benzimidazol-1-yl)-N-(1, 1-dimethyl-2-(2-(1-methyl-4-piperidinyl)phenyl)ethyl)-6-(4-morpholinyl)-; 4-(2-(Difluoromethyl)benzimidazol-1-yl)-N-(1, 1-dimethyl-2-(2-(1-methyl-4-piperidyl)phenyl)ethyl)-6-morpholino-1, 3, 5-triazin-2-amine; 4-[2-(difluoromethyl)benzimidazol-1-yl]-N-[1, 1-dimethyl-2-[2-(1-methyl-4-piperidyl)phenyl]ethyl]-6-morpholino-1, 3, 5-triazin-2-amine; ME 401; RefChem:195844; PI3K-delta Inhibitor PWT143; Me-401; PWT-143; Zandelisib [INN]; Zandelisib [USAN]; 4-[2-(difluoromethyl)benzimidazol-1-yl]-N-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1, 3, 5-triazin-2-amine; 4-[2-(difluoromethyl)-1H-1, 3-benzodiazol-1-yl]-N-{2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl}-6-(morpholin-4-yl)-1, 3, 5-triazin-2-amine; 4-(2-(Difluoromethyl)-1H-Benzo[D]Imidazol-1-Yl)-N-(2-Methyl-1-(2-(1-Methylpiperidin-4-Yl)Phenyl)Propan-2-Yl)-6-Morpholino-1, 3 and 5-Triazin-2-Amine
4-[2-(difluoromethyl)benzimidazol-1-yl]-N-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1, 3 and 5-triazin-2-amine
InChI=1S/C31H38F2N8O/c1-31(2,20-22-8-4-5-9-23(22)21-12-14-39(3)15-13-21)38-28-35-29(40-16-18-42-19-17-40)37-30(36-28)41-25-11-7-6-10-24(25)34-27(41)26(32)33/h4-11,21,26H,12-20H2,1-3H3,(H,35,36,37,38)